Use of beta-adrenergic inverse agonists for smoking cessation
US9993444B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 9, 2012 |
| Grant date | Jun 12, 2018 |
| Priority date | — |
| Expiry date | Apr 29, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/7023
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The chronic use of p-adrenergic inverse agonists such as nadolol, carvedilol, and ICI-118,551 provides an improved method for the treatment of mucus hypersecretion in subjects with such mucus hypersecretion. One aspect of a method according to the present invention is a method of preventing or controlling mucus hypersecretion in the respiratory tract comprising administering a therapeutically effective quantity of a p-adrenergic inverse agonist to a subject with mucus hypersecretion or at risk of mucus hypersecretion. The invention further encompasses pharmaceutical compositions comprising the p-adrenergic inverse agonist and the additional compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.